Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 3,607 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Agent 2 Clear all

Conditions: Non Hodgkin Lymphoma, High-grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma
Interventions: Cyclophosphamide, Alemtuzumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Amivantamab, Docetaxel; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Irvine, California • Los Alamitos, California • Orange, California + 3 more

Conditions: HIV Infections
Interventions: Saquinavir, Lamivudine, Zidovudine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Los Angeles, California • Fort Lauderdale, Florida

Conditions: Neurofibromatosis 1, Plexiform Neurofibroma
Interventions: Cabozantinib Oral Tablet, Selumetinib Oral Capsule; Drug
Lead sponsor: Girish Dhall, MD; Other
Eligibility: 16 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 5 more

Conditions: HIV Prevention
Interventions: emtricitabine 200mg/tenofovir 300mg; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Male only
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Colon Adenocarcinoma, Colorectal Cancer
Interventions: TAS-102, Irinotecan, Standard Treatment, Signatera MRD ctDNA Assay; Drug · Combination Product · Diagnostic Test
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Orange, California

Conditions: Breast Cancer
Interventions: Gedatolisib, Faslodex, Palbociclib, Zoladex; Drug
Lead sponsor: Hoffman Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Los Angeles, California • The Bronx, New York

Conditions: HIV Infections, Pregnancy
Interventions: Nelfinavir mesylate, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 7
States / cities: Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 3 more

Conditions: Heart Failure, Systolic, Frailty
Interventions: sacubitril/valsartan, Angiotensin II Receptor Blockers; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 65 Years and older
Enrollment: 40,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Opioid Use Disorder, Opioid Use, Opioid Abuse, Opioid Misuse, Opioid Dependence
Interventions: buprenorphine/naloxone; Drug
Lead sponsor: Bicycle Health; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Disease, Blocked Arteries, Coronary Ischemia, Coronary Disease, Coronary Artery Disease, Coronary Atherosclerosis
Interventions: MESENDO, placebo; Biological · Other
Lead sponsor: TCA Cellular Therapy; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Covington, Louisiana

Conditions: Solid Tumors, Lung Cancer
Interventions: BKM120, Everolimus; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Heart Failure
Interventions: LCZ 696, Icatibant, placebo, Para-aminohippurate, Iohexol; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Small Cell Lung Cancer
Interventions: Alisertib, Placebo, Paclitaxel; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 21
States / cities: Los Angeles, California • Sacramento, California • New Haven, Connecticut + 18 more

Conditions: HIV Infections
Interventions: Saquinavir, Nevirapine, Zidovudine, Zalcitabine; Drug
Lead sponsor: Parexel; Industry
Eligibility: 13 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Depressive Disorder
Interventions: Carbidopa/levodopa, Placebo, Exercise training, Control; Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 60 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer
Interventions: Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 890 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 7 more

Conditions: Medical Oncology
Interventions: BAY1217389, Paclitaxel; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 6
States / cities: Santa Monica, California • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Small Cell Lung Cancer (SCLC)
Interventions: Pembrolizumab, Normal saline solution, Carboplatin, Cisplatin, Etoposide; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 27
States / cities: Miami, Florida • Chicago, Illinois • Evanston, Illinois + 21 more

Conditions: Intra Abdominal Infections
Interventions: Ertapenem, Sulopenem-Etzadroxil/Probenecid, Ciprofloxacin, Metronidazole, Amoxicillin-Clavulanate, Sulopenem; Drug
Lead sponsor: Iterum Therapeutics, International Limited; Industry
Eligibility: 18 Years and older
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 12
States / cities: Chula Vista, California • Torrance, California • Idaho Falls, Idaho + 8 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: repaglinide, metformin, repaglinide and metformin combination tablet; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Neoplasms, Head and Neck
Interventions: Lapatinib, Chemoradiation, Placebo; Drug · Radiation · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 688 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 5
States / cities: Springfield, Illinois • St Louis, Missouri • New York, New York + 2 more

Conditions: Coronary Artery Disease
Interventions: TAXUS Liberté Paclitaxel-Eluting Coronary Stent, prasugrel, placebo, aspirin; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 4,199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 82
States / cities: Mesa, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 72 more

Conditions: Mucositis, Neoplasms
Interventions: Oral Defense Toothpaste, Crest Toothpaste, Magic Mouth Rinse; Drug
Lead sponsor: Oral Defense, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Spokane, Washington

Search by objective public record fields.

Cyclophosphamide and Alemtuzumab In Lymphoma

A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer

A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas

A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty

Novel Induction to Buprenorphine/Naloxone

Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)

A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection

Levodopa and Exercise for Older Adults With Depression and Psychomotor Slowing

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)

Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers

Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery

TAXUS Libertē Post Approval Study

Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis